The lawsuit alleges three manufacturers coordinated with three pharmacy benefit managers in a scheme to inflate insulin ...
Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...
HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback